TempraMed Technologies (HAM:9DY) Debt-to-Equity: -0.54 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:9DY TempraMed Technologies Ltd HAM:9DY
7 GF Score
Price €0.19
! 5 Warning Signs
View Full Analysis

What is TempraMed Technologies Debt-to-Equity?

TempraMed Technologies HAM:9DY -3.12% 7 Debt-to-Equity is -0.54 as of Jun. 2026. GuruFocus rates HAM:9DY with a GF Score™ of 7/100. The stock has 5 warning signs investors should review. Among 696 Medical Devices & Instruments companies, TempraMed Technologies ranks worse than 143678.02% on this metric.

TempraMed Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €0.94 Mil. TempraMed Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €0.44 Mil. TempraMed Technologies's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €-2.56 Mil. TempraMed Technologies's debt to equity for the quarter that ended in Jun. 2026 was -0.54.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for TempraMed Technologies's Debt-to-Equity or its related term are showing as below:

HAM:9DY' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.74   Med: -0.67   Max: -0.54
Current: -0.54

During the past 3 years, the highest Debt-to-Equity Ratio of TempraMed Technologies was -0.54. The lowest was -1.74. And the median was -0.67.

HAM:9DY's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.24 vs HAM:9DY: -0.54

TempraMed Technologies  (HAM:9DY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

TempraMed Technologies Debt-to-Equity Related Terms

TempraMed Technologies Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for TempraMed Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TempraMed Technologies Debt-to-Equity Chart

TempraMed Technologies Annual Data
Trend Dec23 Dec24 Dec25
Debt-to-Equity
0.00 -0.66 -0.67

TempraMed Technologies Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.74 -1.56 -0.67 -0.64 -0.54

HAM:9DY vs ABT, SYK, MDT: Debt-to-Equity Comparison

For the Medical Devices subindustry, TempraMed Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TempraMed Technologies Debt-to-Equity vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TempraMed Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where TempraMed Technologies's Debt-to-Equity falls into.


HAM:9DY
7GF Score
TempraMed Technologies Ltd HAM:9DY
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TempraMed Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

TempraMed Technologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.687 + 0.39) / -1.602
=-0.67

TempraMed Technologies's Debt to Equity Ratio for the quarter that ended in Jun. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.944 + 0.437) / -2.555
=-0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.54 mean?
TempraMed Technologies (HAM:9DY) has a Debt-to-Equity of -0.54 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TempraMed Technologies and its competitors. According to the industry distribution chart, TempraMed Technologies ranks #999999 out of 696 companies in the Medical Devices & Instruments industry.
Is TempraMed Technologies' Debt-to-Equity too high?
TempraMed Technologies' current Debt-to-Equity is -0.54. Based on the distribution chart, TempraMed Technologies ranks #999999 out of 696 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TempraMed Technologies has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does TempraMed Technologies' Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, TempraMed Technologies ranks #999999 out of 696 companies for Debt-to-Equity. This places TempraMed Technologies in the lower half of its industry. The industry median Debt-to-Equity is 0.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 696 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TempraMed Technologies and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TempraMed Technologies's current Debt-to-Equity is -0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TempraMed Technologies stock overvalued right now?
TempraMed Technologies (HAM:9DY) has a current Debt-to-Equity of -0.54. The current Debt-to-Equity is -0.54. TempraMed Technologies' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For TempraMed Technologies (HAM:9DY), the current Debt-to-Equity is -0.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TempraMed Technologies Business Description

Other Exchanges VIVI:Canada
Address Heh B’Iyar 14, Tel-Aviv, ISR, 6209307
TempraMed Technologies Ltd through its subsidiary, engaged in developing patent-protected technology designed to serve a broad range of medical and consumer products. TempraMed's primary focus is revolutionizing storage and management of injectable for temperature-sensitive medications. This inventive technology ensures adequate temperature storage conditions to medications without requiring power source or human intervention for years.
7GF Score

Get the complete analysis for HAM:9DY

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price